ARTICLE | Company News
Altacor, Proximagen deal
December 5, 2011 8:00 AM UTC
The companies partnered to develop Proximagen's programs targeting the serotonin (5-HT2C) receptor for ophthalmic indications. Altacor will fund preclinical work of PRX00933, the lead compound under...